Humacyte, Inc. is a commercial-stage biotechnology platform company founded in 2004 that develops acellular tissue engineered vessels (ATEVs). Its sole approved product, Symvess, is a bioengineered vascular graft approved for commercial sale in the United States. The company also has pipeline candidates targeting hemodialysis AV access, peripheral artery disease (PAD), coronary artery bypass grafting (CABG), and biologics for vascular procedures, while pursuing international marketing approvals.
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001818382-26-000004 | EDGAR | 121K words |
| 2025-03-31 | 2024-12-31 | 0001818382-25-000034 | EDGAR | 103K words |
| 2024-03-28 | 2023-12-31 | 0001818382-24-000040 | EDGAR | 95K words |
| 2023-03-24 | 2022-12-31 | 0001818382-23-000016 | EDGAR | 98K words |
| 2022-03-29 | 2021-12-31 | 0001818382-22-000011 | EDGAR | — |
| 2021-02-16 | 2020-12-31 | 0001213900-21-009571 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001193125-26-347022 | EDGAR | 42K words |
| 2025-11-12 | 2025-09-30 | 0001818382-25-000132 | EDGAR | 37K words |
| 2025-08-11 | 2025-06-30 | 0001818382-25-000125 | EDGAR | 36K words |
| 2025-05-13 | 2025-03-31 | 0001818382-25-000076 | EDGAR | 33K words |
| 2024-11-08 | 2024-09-30 | 0001818382-24-000199 | EDGAR | 32K words |
| 2024-08-13 | 2024-06-30 | 0001818382-24-000156 | EDGAR | 27K words |
| 2024-05-13 | 2024-03-31 | 0001818382-24-000056 | EDGAR | 25K words |
| 2023-11-09 | 2023-09-30 | 0001818382-23-000162 | EDGAR | 29K words |
| 2023-08-14 | 2023-06-30 | 0001818382-23-000114 | EDGAR | 30K words |
| 2023-05-12 | 2023-03-31 | 0001818382-23-000030 | EDGAR | 26K words |
| 2022-11-10 | 2022-09-30 | 0001818382-22-000180 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001818382-22-000105 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-28 | 0001818382-26-000011 | EDGAR | 1K words |
| 2026-08-12 | 0001104659-26-094440 | EDGAR | 5K words |
| 2026-07-31 | 0001104659-26-089281 | EDGAR | 1K words |
| 2026-03-19 | 0001104659-26-032116 | EDGAR | 17K words |
| 2026-03-19 | 0001104659-26-031780 | EDGAR | 6K words |
| 2025-12-16 | 0001104659-25-121674 | EDGAR | 23K words |
| 2025-12-15 | 0001104659-25-121214 | EDGAR | 47K words |
| 2025-12-15 | 0001104659-25-120915 | EDGAR | 1K words |
| 2025-11-26 | 0001104659-25-116476 | EDGAR | 1K words |
| 2025-11-12 | 0001104659-25-109718 | EDGAR | 4K words |
115 total filings indexed. 87 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001818382 |
| Ticker | HUMA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.humacyte.com |
| Listed | 2021-08-27 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/HUMA (~200 tokens, structured JSON with cryptographic provenance)